ClinicalTrials.gg
CompletedNCT01662999Updated May 8, 2015Results posted

Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants

A Phase 1 interventional study of Saxagliptin and Dapagliflozin in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. saxagliptin · Diabetes Mellitus, Type 2.

Enrollment
51st of 74
42 · median 138
Started
2012
with 11 others
Phase 1
14 of 74
none open now
Registered
43rd of 74
by date
Lead sponsor
48 of 74
AstraZeneca

Among the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment, is one of 12 that started in 2012, is one of 14 in phase 1, and was the 43rd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 74 studies testing saxagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About saxagliptin

saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies testing saxagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate whether the pharmacokinetics (body concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when they are administered together

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, Physical Examination, vital signs, 12-lead , and clinical laboratory determinations
  • (BMI) of 18 to 30 kg/m2
  • Men and women, ages 18 to 45 years
  • Women of must use acceptable methods of highly effective

Exclusion criteria

Exclusion Criteria:

  • History of chronic or recurrent urinary tract infection for females
  • History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or Sodium-glucose transporter type 2 (SGLT2) inhibitors
  • Any significant acute or chronic medical illness
  • Current or recent gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • Prior exposure to saxagliptin or dapagliflozin or related drugs
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)

    Treatment A: Saxagliptin 5mg, Tablet, Oral; Single dose Treatment B: Dapagliflozin 10mg, Tablet, Oral; single dose Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral; single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-Dapagliflozin

    Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    B-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)

    Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose. Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-Saxagliptin

    Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose; Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    C-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-Dapagliflozin

    Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

  • Experimental
    C-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin

    Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg, Tablets, Oral, single dose; Treatment B: Dapagliflozin 10mg, Tablet, Oral, Once daily, single dose; Treatment A: Saxagliptin 5mg, Tablet, Oral, single dose

    Drug: Saxagliptin · Drug: Dapagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population

    The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography-Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program ™. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.

    Time frame: Day 1 (0 h to 60 h post dose) in each period

  2. Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

    AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  3. Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin

    AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method). Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  4. Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in nanograms per milliliter (ng/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  5. AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  6. AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

Secondary outcomes

  1. Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.

    Time frame: Day 1 (0h to 60h post dose) in each period

  2. Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.

    Time frame: Day 1 (0h to 60h post dose) in each period

  3. Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute (mL/min).

    Time frame: Day 1 (0h to 60h post dose) in each period

  4. Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in ng/mL.

    Time frame: Day 1 (0h to 60h post dose) in each period

  5. AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™. AUC (0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  6. AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0h to 60h post dose) in each period

  7. Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety. Measurement was in nano Molars (nM).

    Time frame: Day 1 (0h to 60h post dose) in each period

  8. AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program ™. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars\*hours (nM\*h).

    Time frame: Day 1 (0h to 60h post dose) in each period

  9. Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.

    Time frame: Day 1 (0h to 60h post dose) in each period

  10. Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours (h).

    Time frame: Day 1 (0h to 60h post dose) in each period

  11. Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable

    Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively. Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).

    Time frame: Day 1 (0h to 60h post dose) in each period

  12. Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population

    Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).

    Time frame: Day 1 to end of study (16 days)

  13. Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population

    Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (vol): \<0.85\*pre-RX; erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN; neutrophils+bands (\*10\^9 c/L): \<0.85\*Pre-RX if Pre-RX \<1.5 or \<1.5 if Pre-RX \>=1.5; eosinophils (\*10\^9 c/L): if value \>0.75; basophils (\*10\^9 c/L): if value \>0.4; monocytes (\*10\^9c/L): if value \>2; lymphocytes (\*10\^9 c/L): if value \<0.750 or if value \>7.50.

    Time frame: Baseline to Day 1 of each period

  14. Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population

    Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.

    Time frame: Baseline to Day 1 of each period

  15. Mean Change From Baseline in Heart Rate - Safety Population

    Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

    Time frame: Baseline to Day 1 in each period

  16. Mean Change From Baseline in Respiration Rate - Safety Population

    Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

    Time frame: Baseline to Day 1 in each period

  17. Mean Change From Baseline in Temperature - Safety Population

    Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

    Time frame: Baseline to Day 1 in each period

  18. Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population

    Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-Rx \>ULN or \>1.25\*ULN if Pre-Rx \<=ULN; aspartate aminotransferase (AST) U/L: \>1.25\*Pre-Rx if Pre-Rx \> ULN or 1.25\*ULN if Pre-Rx \<= ULN;alanine aminotransferase (ALT) U/L: \>1.25\*Pre-Rx if Pre-Rx\>ULN or 1.25\*ULN if Pre-Rx\<=ULN;blood urea nitrogen (BUN)mmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.2\*Pre-Rx if Pre-Rx \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.25\*Pre-Rx if Pre-Rx \>ULN;direct bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<= ULN or \>1.25\*Pre-Rx if Pre-Rx \> ULN; creatine phosphokinase (CK) U/L: \>1.5\*Pre-Rx if Pre-Rx \>ULN or \>1.5\*ULN if Pre-Rx \<= ULN.

    Time frame: Baseline to Day 1 in each period

  19. Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population

    Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick \>=1 if Pre-Rx \<1 or 2\*Pre-Rx if Pre-Rx\>=1; urine microscopic white blood cell count (WBC): \>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2;urine red blood cell count (RBC):\>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2.

    Time frame: Baseline to Day 1 of each period

  20. Number of Participants With Change From Baseline in ECG Interval - Safety Population

    A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes. ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF \>450 msec and \<=480 msec at any postdose time point and not present at baseline. QT or QTcF \>480 msec and \<=500 msec at any postdose time point and not present at baseline QT or QTcF \>500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline \>60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF \>30 msec for at least 1 postdose measurement, but \<=60 msec for all postdose measurements.

    Time frame: Baseline to end of study (16 days)

07

Results

Posted Dec 23, 2013

Participant flow

20 August 2012 to 29 November 2012. Phase 1 Clinical Pharmacology center with healthy, fasted participants.

Period 1
Participant flow — Period 1
MilestoneA-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin
Started777777
Completed777777
Not completed000000
Period 2
Participant flow — Period 2
MilestoneA-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin
Started777777
Completed777777
Not completed000000
Period 3
Participant flow — Period 3
MilestoneA-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin
Started777777
Completed767777
Not completed010000
Withdrew: Withdrawal by subject010000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population

The geometric mean of the maximum observed plasma concentration (Cmax) is presented below; serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h,and 60 h postdose, relative to dosing on Day 1 in each cross over period and these data are summarized in the Pharmacokinetic (PK) parameter of Cmax presented here. Plasma samples were analyzed for dapagliflozin by High Performance Liquid chromatography-Mass Spectrometry (HPLC-MS/MS) using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Dapagliflozin Cmax was derived from plasma concentration versus time data using a non-compartmental method, using a validated PK analysis program ™. Actual sampling times were used for PK calculations. Cmax was reported in ng/mL.

Time frame:
Day 1 (0 h to 60 h post dose) in each period
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population
ng/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Maximum Observed Plasma Concentration (Cmax) of Dapagliflozin From a Single Dose of Dapagliflozin Versus Cmax of Dapagliflozin From Co-administered Saxagliptin Plus Dapagliflozin - Pharmacokinetic Evaluable Population133 ± 23125 ± 27
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.943 · 90% CI 0.867 to 1.026
PrimaryArea Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

AUC(INF) is area under the plasma concentration-time curve from time 0 extrapolated to infinity. Serial blood samples for determination of study drug were collected predose (0 hours (h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(INF) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
ng*h/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Area Under the Concentration-time Curve (AUC) From Time Zero to Infinity [AUC(INF)] of Dapagliflozin From a Single Dose of Dapagliflozin Versus AUC (INF) of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population547 ± 23539 ± 20
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ration of adjusted geometric mean: 0.984 · 90% CI 0.961 to 1.008
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. Tmax was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Median · hours
Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population
hours10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Time of Maximum Observed Plasma Concentration (Tmax) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus Tmax of Dapagliflozin When Co-administered With 5 mg Saxagliptin - PK Evaluable Population1.00 (0.50 to 2.02)1.00 (0.50 to 2.00)
PrimaryArea Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin

AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method). Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method; nominal range of 0.200 to 100 nanograms per milliliter (ng/mL). Actual sampling times were used for PK calculations. AUC(0-T) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin
ng*h/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Area Under the Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration AUC(0-T) of Dapagliflozin From a Single Dose of 10 mg Dapagliflozin Versus AUC(0-T) for Dapagliflozin When Co-administered With 5 mg Saxagliptin529 ± 23523 ± 19
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.990 · 90% CI 0.966 to 1.014
SecondaryHalf-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours.

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Mean · hours
Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
hours10mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Half-life (T-HALF) of Dapagliflozin From a Single Dose of Dapagliflozin Versus T-Half of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population15.9 ± 7.3213.8 ± 4.81
PrimaryMaximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). Cmax for Saxagliptin was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in nanograms per milliliter (ng/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
ng/mL5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
Maximum Observed Concentration (Cmax) of a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population23.6 ± 3121.9 ± 33
Statistical analysis
  • 5 mg Saxagliptin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.927 · 90% CI 0.883 to 0.972
SecondaryPlasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for dapagliflozin by HPLC-MS/MS using a validated method. Actual sampling times were used for PK calculations. CLT/F was calculated as Dose/AUC(INF)and was measured in milliliters per minute (mL/min).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · mL/min
Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population
mL/min10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Plasma Apparent Clearance (CLT/F) of a Single Dose of Dapagliflozin Versus CLT/F of Dapagliflozin When Co-administered With Saxagliptin - PK Evaluable Population305 ± 24309 ± 20
SecondaryCmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). Actual sampling times were used for PK calculations. Cmax for 5-OH Saxagliptin (the major active metabolite of Saxagliptin) was derived from plasma concentration versus time data using a validated PK analysis program ™ and was measured in ng/mL.

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng/mL
Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
ng/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
Cmax of 5-Hydroxy (5-OH) Saxagliptin From a Single Dose Saxagliptin Versus Cmax of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population47.0 ± 3049.6 ± 27
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 1.055 · 90% CI 1.004 to 1.109
PrimaryAUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by Liquid chromatography-Mass Spectrometry (LC-MS/MS) using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(0-T), the area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
ng*h/mL5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
AUC(0-T) of Saxagliptin From Single Dose 5 mg Saxagliptin Versus AUC(0-T) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population87.8 ± 2387.0 ± 23
Statistical analysis
  • 5 mg Saxagliptin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.991 · 90% CI 0.960 to 1.022
PrimaryAUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
ng*h/mL5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
AUC(INF) of Saxagliptin From a Single Dose of 5 mg Saxagliptin Versus AUC(INF) of Saxagliptin When Co-administered With 10 mg Dapagliflozin - PK Evaluable Population89.0 ± 2388.2 ± 23
Statistical analysis
  • 5 mg Saxagliptin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.991 · 90% CI 0.961 to 1.022
SecondaryAUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method)and was derived from the plasma concentration versus time profile for study drug using a validated PK analysis program ™. AUC (0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population
ng*h/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
AUC(0-T) of 5-OH Saxagliptin From Single Dose Saxagliptin Versus AUC(0-T) of 5-OH From Saxagliptin Co-administered With Dapagliflozin - PK Evaluable Population267 ± 22289 ± 22
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 1.085 · 90% CI 1.058 to 1.113
SecondaryAUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.200 ng/mL to 100.0 ng/mL). AUC(INF) was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · ng*h/mL
AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
ng*h/mL10 mg Dapagliflozin5 mg Saxagliptin + 10 mg Dapagliflozin
AUC(INF) of 5-OH Saxagliptin From a Single Dose Saxagliptin Versus AUC(INF) of 5-OH When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population273 ± 22296 ± 22
Statistical analysis
  • 10 mg Dapagliflozin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 1.085 · 90% CI 1.058 to 1.113
SecondaryCmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Cmax of saxagliptin total active moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin) was derived from the plasma concentration versus time profile for the saxagliptin total active moiety. Measurement was in nano Molars (nM).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · nM
Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
nM5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
Cmax of the Saxagliptin Total Active Moiety From a Single Dose of 5 mg Saxagliptin Versus Cmax of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population138 ± 20137 ± 21
Statistical analysis
  • 5 mg Saxagliptin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 0.994 · 90% CI 0.960 to 1.030
SecondaryAUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. AUC(INF) is area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC(0-T) is area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (linear up/log down trapezoidal method) and both were derived from the plasma concentration versus time profile using a validated PK analysis program ™. Total moiety (molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin), AUC(0-T)and AUC(INF) were measured in nano Molars\*hours (nM\*h).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · nM*h
AUC(INF) and AUC(0-T) of the Saxagliptin Total Active Moiety From a Single Dose 5 mg Saxagliptin Versus AUC(INF) and AUC(0-T) of Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable Population
nM*h5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
AUC(INF) for Saxagliptin Total Active Moiety702 ± 15735 ± 15
AUC(0-T) for Saxagliptin Total Active Moiety694 ± 15727 ± 15
Statistical analysis
  • 5 mg Saxagliptin vs 5 mg Saxagliptin + 10 mg Dapagliflozin · Mixed Models Analysis · Ratio of adjusted geometric mean: 1.046 · 90% CI 1.029 to 1.064
SecondaryTmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin and 5-OH by LC-MS/MS using a validated method. Tmax was derived from the plasma concentration versus time profile for study drug and was measured in hours (h). Saxagliptin was the drug, 5-OH saxagliptin was the metabolite, and Saxagliptin total Active Moiety was molar summations of saxagliptin exposure parameter with one-half the molar exposure parameters for 5-OH Saxagliptin.

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Median · h
Tmax of Saxagliptin, 5-OH Saxagliptin, Saxagliptin Total Active Moiety From a Single Dose of Saxagliptin Versus Tmax of Saxagliptin, 5-OH, Saxagliptin Total Active Moiety When Saxagliptin Was Co-administered With Dapagliflozin - PK Evaluable Population
h5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
Tmax of Saxagliptin0.50 (0.50 to 2.00)1.00 (0.50 to 2.00)
Tmax of 5-OH Saxagliptin1.50 (1.00 to 2.00)1.50 (1.00 to 3.00)
Tmax of Saxagliptin Total Active Moiety1.00 (0.50 to 2.00)1.00 (0.50 to 2.00)
SecondaryHalf-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Plasma samples were analyzed for saxagliptin by LC-MS/MS using a validated method. T-HALF was derived from the plasma concentration versus time profile using a validated PK analysis program ™ and was measured in hours (h).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Mean · h
Half-life (T-HALF) of Saxagliptin, and 5-OH Saxagliptin From Single Dose 5 mg Saxagliptin Versus T-HALF of Saxagliptin and 5-OH From Co-administered Saxagliptin With 10 mg Dapagliflozin - PK Evaluable Population
h5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
T-HALF for Saxagliptin5.86 ± 2.235.38 ± 2.17
T-HALF for 5-OH Saxagliptin15.9 ± 3.0617.0 ± 2.97
SecondaryMetabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable

Serial blood samples for determination of study drug were collected predose (0 h), 6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h and 60 h postdose, relative to dosing on Day 1 in each cross over period. Saxagliptin is the parent drug and 5-OH saxagliptin is the metabolite. The molecular weights to be used for the molar ratios were 315.42 and 331.42 for saxagliptin and 5-OH, respectively. Plasma samples were analyzed for saxagliptin and for 5-OH by LC-MS/MS using a validated method (quantitation range of 0.100 ng/mL to 50.0 ng/mL and 0.200 ng/mL to 100.0 ng/mL for saxagliptin and 5-OH, respectively).

Time frame:
Day 1 (0h to 60h post dose) in each period
Reported as:
Geometric mean · Molar ratio
Metabolite to Parent Molar Ratios (MR) of Cmax, AUC(INF), and AUC(0-T) of 5-OH Saxagliptin and Saxagliptin From a Single Dose 5 mg Saxagliptin Versus MR of Saxagliptin and 5-OH When Saxagliptin Was Co-administered With 10 mg Dapagliflozin - PK Evaluable
Molar ratio5 mg Saxagliptin5 mg Saxagliptin + 10 mg Dapagliflozin
MR_Cmax1.90 ± 372.16 ± 37
MR_AUC(INF)2.92 ± 333.19 ± 33
MR_AUC(0-T)2.89 ± 333.16 ± 34
SecondaryNumber of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population

Adverse event (AE)=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE)=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. End of study was approximately 16 days and was the time for a participant to conclude each of the 3 periods (including the 6 day washout between periods).

Time frame:
Day 1 to end of study (16 days)
Reported as:
Number · participants
Number of Participants With Deaths, Serious Adverse Events, Adverse Events, or Discontinuations Due to Adverse Events - Safety Population
participantsTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Participants with AEs698
Participants with treatment-related AEs447
Participants with SAEs000
Participants discontinuing due to AEs000
Deaths000
SecondaryNumber of Participants With Marked Hematology Laboratory Abnormalities - Safety Population

Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal (LLN); upper limit of normal (ULN); pretreatment(pre-RX); treatment (RX). Hemoglobin (g/L): \<0.85\* pre-RX; hematocrit (vol): \<0.85\*pre-RX; erythrocytes (\*10\^12 c/L): \<0.85\*pre-RX; platelet count (\*10\^9 c/L): \<0.85\*LLN if pre-RX\>=LLN, or if Pre-Tx \<LLN; leukocytes (\*10\^9 c/L): \<0.85\*LLN if pre-RX \<LLN,or \<0.9\*LLN if LLN\<=Pre-RX\<=ULN; neutrophils+bands (\*10\^9 c/L): \<0.85\*Pre-RX if Pre-RX \<1.5 or \<1.5 if Pre-RX \>=1.5; eosinophils (\*10\^9 c/L): if value \>0.75; basophils (\*10\^9 c/L): if value \>0.4; monocytes (\*10\^9c/L): if value \>2; lymphocytes (\*10\^9 c/L): if value \<0.750 or if value \>7.50.

Time frame:
Baseline to Day 1 of each period
Reported as:
Number · participants
Number of Participants With Marked Hematology Laboratory Abnormalities - Safety Population
participantsTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Leukocytes Low001
Neutrophils (absolute) Low111
SecondaryMean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population

Blood pressure was taken while the participant was quietly seated for at least 5 minutes. Blood pressure was measured in millimeters of mercury (mmHg). Baseline was Day -1 in Period 1; study drug was administered on Day 1 of each crossover period.

Time frame:
Baseline to Day 1 of each period
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic and Diastolic Blood Pressure - Safety Population
mmHgTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Systolic Blood Pressure-6.0 ± 7.41-4.6 ± 8.13-7.2 ± 8.35
Diastolic Blood Pressure-2.6 ± 4.94-2.0 ± 4.86-3.3 ± 6.23
SecondaryMean Change From Baseline in Heart Rate - Safety Population

Heart rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in beats per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

Time frame:
Baseline to Day 1 in each period
Reported as:
Mean · bpm
Mean Change From Baseline in Heart Rate - Safety Population
bpmTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Mean Change From Baseline in Heart Rate - Safety Population-4.4 ± 7.04-4.0 ± 9.64-4.3 ± 10.52
SecondaryMean Change From Baseline in Respiration Rate - Safety Population

Respiration rates were taken while the participant was sitting quietly for at least 5 minutes and were measured in breaths per minute (bpm). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

Time frame:
Baseline to Day 1 in each period
Reported as:
Mean · bpm
Mean Change From Baseline in Respiration Rate - Safety Population
bpmTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Mean Change From Baseline in Respiration Rate - Safety Population-0.4 ± 3.46-1.2 ± 2.89-0.9 ± 3.13
SecondaryMean Change From Baseline in Temperature - Safety Population

Participant had their temperature taken after quietly sitting for at least 5 minutes and it was measured as degrees of centigrade (C). Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period.

Time frame:
Baseline to Day 1 in each period
Reported as:
Mean · degrees of centigrade
Mean Change From Baseline in Temperature - Safety Population
degrees of centigradeTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Mean Change From Baseline in Temperature - Safety Population-0.15 ± 0.393-0.23 ± 0.383-0.16 ± 0.385
SecondaryNumber of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population

Fasted for 10 hours prior to samples taken. Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Lower limit of normal(LLN); upper limit of normal (ULN); pre-treatment(Pre-Rx). Alkaline phosphatase U/L:\>1.25\*Pre-RX if Pre-Rx \>ULN or \>1.25\*ULN if Pre-Rx \<=ULN; aspartate aminotransferase (AST) U/L: \>1.25\*Pre-Rx if Pre-Rx \> ULN or 1.25\*ULN if Pre-Rx \<= ULN;alanine aminotransferase (ALT) U/L: \>1.25\*Pre-Rx if Pre-Rx\>ULN or 1.25\*ULN if Pre-Rx\<=ULN;blood urea nitrogen (BUN)mmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.2\*Pre-Rx if Pre-Rx \>ULN; total bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<=ULN or \>1.25\*Pre-Rx if Pre-Rx \>ULN;direct bilirubin µmol/L: \>1.1\*ULN if Pre-Rx \<= ULN or \>1.25\*Pre-Rx if Pre-Rx \> ULN; creatine phosphokinase (CK) U/L: \>1.5\*Pre-Rx if Pre-Rx \>ULN or \>1.5\*ULN if Pre-Rx \<= ULN.

Time frame:
Baseline to Day 1 in each period
Reported as:
Number · participants
Number of Participants With Marked Chemistry Laboratory Abnormalities - Safety Population
participantsTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Total Bilirubin High111
Direct Bilirubin High111
ALT High101
BUN High100
CK High001
SecondaryNumber of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population

Baseline was Day -1 of Period 1; study drug was administered on Day 1 of each crossover period. Fasted for 10 hours prior to samples taken. LLN=lower limit of normal; ULN=upper limit of normal; pretreatment (Pre-Rx). Normals: Urine glucose qualitative: dipstick \>=1 if Pre-Rx \<1 or 2\*Pre-Rx if Pre-Rx\>=1; urine microscopic white blood cell count (WBC): \>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2;urine red blood cell count (RBC):\>=2 if Pre-Rx \<2 or \>=4 if Pre-Rx \>=2.

Time frame:
Baseline to Day 1 of each period
Reported as:
Number · participants
Number of Participants With Marked Urinalysis Laboratory Abnormalities - Safety Population
participantsTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
Urine Glucose High (N=42, 42, 42)025
Urine WBC and RBC High (N= 4, 8, 6)001
SecondaryNumber of Participants With Change From Baseline in ECG Interval - Safety Population

A 12-Lead electrocardiogram (ECG) was performed and recorded after the participant had been supine for at least 5 minutes. ECGs done at baseline (Day-1 of Period 1) and at end of study; therefore the results are presented by sequence, and cannot be presented by treatment. QT interval (measure between Q wave and T wave in the heart's electrical cycle); and QT interval corrected for heart rate using Fridericia's formula (QTcF) were measured in milliseconds (msec). Abnormality criteria: QT/QTcF QT or QTcF \>450 msec and \<=480 msec at any postdose time point and not present at baseline. QT or QTcF \>480 msec and \<=500 msec at any postdose time point and not present at baseline QT or QTcF \>500 msec at any postdose time point and not present at baseline. QT/QTcF Increase from baseline \>60 msec for at least 1 postdose measurement. Increase from baseline in QT or QTcF \>30 msec for at least 1 postdose measurement, but \<=60 msec for all postdose measurements.

Time frame:
Baseline to end of study (16 days)
Reported as:
Number · participants
Number of Participants With Change From Baseline in ECG Interval - Safety Population
participantsA-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-Saxagliptin
QT change from baseline >60 msec000100
QT change from baseline >30 msec; <=60 msec040000
QTcF change from baseline >60 msec000000
QTcF change from baseline >30 msec; <=60 msec000000

Adverse events

Collected over Day -1 to end of study (approximately 16 days). Total length of 3 crossover periods.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Saxagliptin 5mg—0/42 (0%)6/42 (14.3%)
Treatment B: Dapagliflozin 10mg—0/42 (0%)9/42 (21.4%)
Treatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg—0/42 (0%)8/42 (19%)
Most frequent other events
Showing 10 of 19
Most frequent other events
EventTreatment A: Saxagliptin 5mgTreatment B: Dapagliflozin 10mgTreatment C: Saxagliptin 5 mg + Dapagliflozin 10 mg
HeadacheNervous system disorders0/422/424/42
ConstipationGastrointestinal disorders2/421/422/42
DysmenorrheaReproductive system and breast disorders0/422/421/42
NauseaGastrointestinal disorders0/422/420/42
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/421/420/42
Abdominal distensionGastrointestinal disorders1/420/420/42
Abdominal painGastrointestinal disorders0/420/421/42
Abdominal Pain LowerGastrointestinal disorders1/420/420/42
ALT increasedInvestigations0/420/421/42
Back painMusculoskeletal and connective tissue disorders1/420/420/42

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
<=18 years0000000
Between 18 and 65 years77777742
>=65 years0000000
Age, Continuous
Age, Continuous(years)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
Mean36.1 ± 6.4728.7 ± 5.0227.7 ± 6.9932.0 ± 6.5134.4 ± 5.7433.3 ± 7.9532.0 ± 6.81
Sex: Female, Male
Sex: Female, Male(Participants)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
Female22232213
Male55545529
Region of Enrollment
Region of Enrollment(participants)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
United States77777742
Body Surface Area (m^2)
Body Surface Area (m^2)(m^2)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
Mean1.90 ± 0.1871.92 ± 0.1451.91 ± 0.2081.95 ± 0.1701.94 ± 0.1661.85 ± 0.1081.91 ± 0.160
Body Weight (kg)
Body Weight (kg)(kg)A-B-C: Saxagliptin-Dapagliflozin-(Saxagliptin+Dapagliflozin)A-C-B: Saxagliptin-(Saxagliptin+Dapagliflozin)-DapagliflozinB-A-C: Dapagliflozin-Saxagliptin-(Saxagliptin+Dapagliflozin)B-C-A: Dapagliflozin-(Saxagliptin+Dapagliflozin)-SaxagliptinC-A-B: (Saxagliptin+Dapagliflozin)-Saxagliptin-DapagliflozinC-B-A: (Saxagliptin+Dapagliflozin)-Dapagliflozin-SaxagliptinTotal
Mean77.94 ± 12.25078.94 ± 8.10076.01 ± 14.58980.73 ± 11.90379.64 ± 11.22371.71 ± 6.40477.50 ± 10.813
08

Study locations

1 site
  • Icon Clinical Pharmacology
    Omaha, Nebraska 68154, United States
09

References and documents

Publications

  • Vakkalagadda B, Lubin S, Reynolds L, Liang D, Marion AS, LaCreta F, Boulton DW. Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study. Clin Ther. 2016 Aug;38(8):1890-9. doi: 10.1016/j.clinthera.2016.07.005. Epub 2016 Aug 2. PubMed 27491280 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2012
First posted
Aug 13, 2012
Start
Aug 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Dec 23, 2013
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01662999
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 13, 2012
Start date
Aug 2012
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Dec 23, 2013
Last update
May 8, 2015

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Saxagliptin · Dapagliflozin

Start the discussion